About

Overview of LUTATHERA^® (lutetium [¹⁷⁷Lu] oxodotreotide)

Novartis currently markets one targeted radioligand therapy in oncology (LUTATHERA) and several precision imaging products mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.

AAA-Lu177-UK-2403 | April 2024

Image of a 3d model of PRRT with two hands approaching the model

Introduction to RLT

Discover the goals and mechanism of action of this innovative cancer treatment strategy

AAA-Lu177-UK-2359 | April 2024

LUTATHERA®▼

Learn more about LUTATHERA^® (lutetium [177Lu] oxodotreotide)

Click here to find out more.

AAA-Lu177-UK-2280 | January 2024

Image of a woman touching an interactive screen. An image of the gastrointestinal system is displayed on the screen.

Introduction to GEP-NETs

Click to access resources and find out more information about GEP-NETs

AAA-Lu177-UK-2146 | October 2023

Image of a man and woman standing behind an interactive screen. There is an image of the earth on the screen

PRRT Practical Resources

Click to access resources and learn more about PRRT.

AAA-Lu177-UK-2157 | October 2023

Image of people's hands together in a huddle

Further support

Access a list of direct links to some of the most useful resources from medical societies, patient groups and other education providers.

AAA-Lu177-UK-1666 | March 2023

About

Background to RLT

About

Overview of LUTATHERA^® (lutetium [¹⁷⁷Lu] oxodotreotide)

Introduction to RLT

Introduction to RLT

LUTATHERA®▼

Learn more about LUTATHERA^® (lutetium [177Lu] oxodotreotide)

Introduction to GEP-NETs

Introduction to GEP-NETs

PRRT Practical Resources

PRRT Practical Resources

Further support

Further support

Ask Speakers

About

Overview of LUTATHERA® (lutetium [177Lu] oxodotreotide)

Ask Speakers

Medical Information Request

Overview of LUTATHERA^® (lutetium [¹⁷⁷Lu] oxodotreotide)